{
    "Trade/Device Name(s)": [
        "Afinion\u2122 Lipid Panel",
        "Afinion\u2122 Lipid Panel Control"
    ],
    "Submitter Information": "Axis-Shield PoC AS",
    "510(k) Number": "K132031",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031824",
        "K972250",
        "K982341",
        "K061182"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "CHH",
        "LBR",
        "JGY",
        "JJX"
    ],
    "Summary Letter Date": "March 21, 2014",
    "Summary Letter Received Date": "February 12, 2014",
    "Submission Date": "February 10, 2014",
    "Regulation Number(s)": [
        "21 CFR 862.1175",
        "21 CFR 862.1475",
        "21 CFR 862.1705",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Cholesterol (total) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Total Cholesterol",
        "HDL Cholesterol",
        "Triglycerides",
        "LDL Cholesterol (calculated)",
        "Non-HDL Cholesterol (calculated)",
        "Chol/HDL ratio (calculated)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Afinion\u2122 AS100 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic colorimetric assay",
        "Antibody-blocking enzymatic assay (for HDL)"
    ],
    "Methodologies": [
        "Quantitative enzymatic colorimetric testing"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Reagent",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Afinion\u2122 Lipid Panel and Afinion\u2122 Lipid Panel Control for quantitative determination of lipid profile in serum using the Afinion\u2122 AS100 Analyzer.",
    "Indications for Use Summary": "In vitro diagnostic test for quantitative determination of total cholesterol, HDL cholesterol, and triglycerides in serum with calculated LDL, non-HDL cholesterol and Chol/HDL ratio, used to aid diagnosis and treatment of blood cholesterol and lipid metabolism disorders in clinical laboratories and point of care settings.",
    "fda_folder": "Clinical Chemistry"
}